A genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile – requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care.
Lead Underwriter
Guggenheim Securities, LLC, J.P. Morgan Securities LLC, Jefferies LLC, William Blair & Company, L.L.C.
